Abstract:Heparin-induced thrombocytopenia with thrombosis (HITT) is a rare complication of cardiac surgery with cardiopulmonary bypass. We report two cases of HITT treated with the direct thrombin inhibitor Lepirudin. Immediate diagnosis was essential to prompt heparin discontinuation and successful early Lepirudin administration in the first case. In the second, the presence of an intra-aortic balloon pump delayed HITT recognition, and Lepirudin infusion could not prevent limb amputation. In both cases HITT occurred e… Show more
“…Thus, should platelet counts decline, clinicians confront the uncertainty of the thrombocytopenia being IABP‐associated or due to heparin‐induced thrombocytopenia (HIT). Although only a small minority of heparinized patients (1–3%) 12–16 experience this reaction, the clinical consequences can be severe 17,18 …”
Section: Introductionmentioning
confidence: 99%
“…Although only a small minority of heparinized patients (1-3%) [12][13][14][15][16] experience this reaction, the clinical consequences can be severe. 17,18 Many contemporary IABP patients are now treated with one or more antiplatelet medications including the glycoprotein IIb/IIIa receptor (GP IIb/IIIa) antagonists (abciximab, eptifibatide, and tirofiban) and the thienopyridine clopidogrel. Both classes have been reported to cause thrombocytopenia.…”
IABP-associated thrombocytopenia occurred in 57.9% of this cohort. HIT was diagnosed in 2.8% and should be considered as a diagnosis if platelet counts do not stabilize or continue to fall after 3-4 days of counterpulsation. Increased use of antiplatelet therapy does not impact the degree of thrombocytopenia although the current practice of prompt IABP removal may offset this effect.
“…Thus, should platelet counts decline, clinicians confront the uncertainty of the thrombocytopenia being IABP‐associated or due to heparin‐induced thrombocytopenia (HIT). Although only a small minority of heparinized patients (1–3%) 12–16 experience this reaction, the clinical consequences can be severe 17,18 …”
Section: Introductionmentioning
confidence: 99%
“…Although only a small minority of heparinized patients (1-3%) [12][13][14][15][16] experience this reaction, the clinical consequences can be severe. 17,18 Many contemporary IABP patients are now treated with one or more antiplatelet medications including the glycoprotein IIb/IIIa receptor (GP IIb/IIIa) antagonists (abciximab, eptifibatide, and tirofiban) and the thienopyridine clopidogrel. Both classes have been reported to cause thrombocytopenia.…”
IABP-associated thrombocytopenia occurred in 57.9% of this cohort. HIT was diagnosed in 2.8% and should be considered as a diagnosis if platelet counts do not stabilize or continue to fall after 3-4 days of counterpulsation. Increased use of antiplatelet therapy does not impact the degree of thrombocytopenia although the current practice of prompt IABP removal may offset this effect.
“…When HITT develops postoperatively, heparin must be discontinued and alternative anticoagulant agents given. Alternative anti coagulant agents are intravenous hirudin, argatroban, danaproid or lepirudin [ 6 - 8 ]. Warfarin is recommended to start simultaneously with hirudin or other alternative anticoagulants except heparin.…”
Background: Delayed-onset heparin-induced thrombocytopenia with thrombosis, albeit rare, is a severe side effect of heparin exposure. It can occur within one month after coronary artery bypass grafting (CABG) with manifestation of different thrombotic events.
A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: Review of immunogenicity and safety.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.